Trans Genic and Kumamoto Foundation Conclude Anti-HIV Antibody License Agreement.Tokyo, Japan, July 19, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Trans Genic genic /gen·ic/ (jen´ik) pertaining to or caused by the genes. gen·ic adj. Of, relating to, produced by, or being genes or a gene. genic pertaining to or caused by the genes. , a biotech company specializing in genome function research, and the Kumamoto Techno Industrial foundation have concluded an exclusive license agreement on anti-HIV antibodies PCT/JP2004/003046. The partners have produced a monoclonal antibody with a high level of neutralization neutralization, chemical reaction, according to the Arrhenius theory of acids and bases, in which a water solution of acid is mixed with a water solution of base to form a salt and water; this reaction is complete only if the resulting solution has neither acidic nor activity against HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. as part of a therapeutic drug for AIDS. The findings were based on experiments on genetically modified mice with high affinity antibody-producing cells. The Kumamoto foundation has filed an application for international patent for the monoclonal antibody. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion